Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Accumulated Expenses (2016 - 2025)

Moleculin Biotech's Accumulated Expenses history spans 10 years, with the latest figure at $1.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $1.8 million for Q4 2025, changed 0.22% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (changed 0.22% YoY), and the annual figure for FY2025 was $1.8 million, changed 0.22%.
  • Accumulated Expenses for Q4 2025 was $1.8 million at Moleculin Biotech, up from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.2 million in Q2 2025 to a low of $106000.0 in Q2 2021.
  • The 5-year median for Accumulated Expenses is $2.1 million (2021), against an average of $2.1 million.
  • The sharpest move saw Accumulated Expenses crashed 94.18% in 2021, then surged 2423.58% in 2022.
  • Year by year, Accumulated Expenses stood at $2.3 million in 2021, then crashed by 66.87% to $748000.0 in 2022, then grew by 2.27% to $765000.0 in 2023, then surged by 137.52% to $1.8 million in 2024, then grew by 0.22% to $1.8 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.8 million, $1.4 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.